2024-11-04 - Analysis Report
##  Pfizer Inc. (PFE) Stock Analysis Report

**1.  Performance and Relative Outperformance**

Pfizer Inc. (PFE) is a global pharmaceutical company that develops and manufactures medicines and vaccines. 

* **Cumulative Return:** -13.87%
* **S&P 500 (VOO) Cumulative Return:** 131.78%
* **Performance Gap:** -145.65%
* **Relative Outperformance:** 2.59% (meaning its performance is in the 2.59th percentile of its historical performance range relative to the S&P 500) 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | 1.4% | 13.9% | 1.0% | 0.0 |
| 2016 | 0.3% | 17.9% | -9.2% | 0.0 |
| 2017 | 11.1% | 7.3% | -8.4% | 0.6 |
| 2018 | 21.2% | 13.3% | 31.9% | -2.0 |
| 2019 | -15.5% | 22.4% | -46.5% | -0.5 |
| 2020 | -2.0% | 29.2% | -22.3% | -0.1 |
| 2021 | 67.7% | 17.4% | 28.5% | 1.7 |
| 2022 | -27.9% | 24.0% | 17.7% | 0.6 |
| 2023 | -69.4% | 42.4% | -104.0% | -2.0 |
| 2024 | -0.8% | 6.2% | -34.3% | -0.0 |

PFE has shown significant volatility, particularly in recent years, with a fluctuating beta coefficient indicating periods of both outperformance and underperformance relative to the market. Notably, the company experienced a considerable negative Alpha in 2023, suggesting underperformance relative to the S&P 500. 

**2. Recent Price Movement**

* **Closing Price:** 28.09 (Last-market: 28.08)
* **5-day Moving Average:** 28.45
* **20-day Moving Average:** 28.99
* **60-day Moving Average:** 28.98

PFE is currently trading slightly below its recent moving averages, suggesting a potential short-term downtrend. 

**3. Technical Indicators**

* **RSI:** 34.29
* **PPO:** -0.34
* **Delta_Previous_Relative_Divergence:** 2.34 (+) (short-term upward trend)
* **Expected Return:** 0.0% (estimated long-term (2+ years) return relative to the S&P 500)

The RSI indicates a slightly oversold condition, while the PPO suggests bearish momentum. The positive Delta_Previous_Relative_Divergence indicates a short-term upward trend, suggesting a potential rebound. However, the expected return of 0.0% suggests that PFE might not outperform the S&P 500 in the long run.

**4. Recent Earnings Performance and Outlook**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

The most recent earnings results (2024-10-29) show an EPS of 1.06, exceeding expectations of 0.614. This suggests that the company is performing better than anticipated. However, the previous earnings reports exhibited a mixed performance, with some quarters exceeding expectations and others falling short.

**5. Financial Information**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $13.28B | $9.98B 75.16% |
| 2024-03-31 | $14.88B | $11.50B 77.29% |
| 2023-12-31 | $14.25B | $6.69B 46.92% |
| 2023-09-30 | $13.23B | $3.96B 29.95% |
| 2023-06-30 | $13.01B | $9.77B 75.11% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |
| 2023-06-30 | $99.02B | 2.35% |

PFE exhibits strong revenue growth and consistent profitability. However, the ROE has been fluctuating, indicating challenges in maximizing shareholder value.

**6. News and Recent Issues**

* **Recent Earnings News:** Refer to recent earnings call transcripts, news releases from Pfizer, and financial news websites like Shacknews for the latest earnings news and analyst commentary.
* **Market Outlook:** Refer to financial websites like Finbold for recent market outlook, analyst opinions, and performance highlights regarding PFE.

**7. Summary**

PFE's stock performance has lagged behind the S&P 500 significantly. While the company has demonstrated strong revenue growth and consistent profitability, its fluctuating ROE and recent underperformance relative to the market raise concerns. The recent earnings report, however, shows positive results, exceeding expectations. Despite a potential short-term rebound, the technical indicators suggest a bearish outlook. The expected long-term return of 0.0% relative to the S&P 500 suggests that investors might need to consider other investment options for long-term growth. 
